Longeveron Inc. (NASDAQ: LGVN) announced Friday a clinical trial collaboration to study its lead investigational asset, Lomecel-B.
What Happened: Florida-based Longeverson said it has entered into a sponsored clinical research agreement with Japan’s National Center for Geriatrics and Gerontology and the Juntendo University Hospital to study Lomcecel-B in older, frail Japanese subjects.
The Japanese Phase 2 study, approved by Japan’s Pharmaceuticals and Medical Devices Agency, has a target enrollment of 45 subjects in three cohorts, randomized to receive a single intravenous infusion of Lomecel-B 50 million cells, Lomecel-B 100 million cells, or a placebo.
The primary objective is to evaluate the safety and explore the effect of Lomecel-B on physical function, activities of daily living, inflammation-related …
Original Article: benzinga.com